X

Xtant Medical Holdings Inc
AMEX:XTNT

Watchlist Manager
Xtant Medical Holdings Inc
AMEX:XTNT
Watchlist
Price: 0.5782 USD 1.44% Market Closed
Market Cap: $80.9m

Gross Margin

60.2%
Current
Improving
by 0.7%
vs 3-y average of 59.4%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
60.2%
=
Gross Profit
$76.9m
/
Revenue
$127.8m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
60.2%
=
Gross Profit
$76.9m
/
Revenue
$127.8m

Peer Comparison

Country Company Market Cap Gross
Margin
US
Xtant Medical Holdings Inc
AMEX:XTNT
80.6m USD
Loading...
US
Medline Inc
NASDAQ:MDLN
63.4B USD
Loading...
JP
Hoya Corp
TSE:7741
9.6T JPY
Loading...
CH
Alcon AG
SIX:ALC
32.9B CHF
Loading...
DK
Coloplast A/S
CSE:COLO B
110.1B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
13.6B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
5B GBP
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6.5B USD
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
41.1B CNY
Loading...
JP
Asahi Intecc Co Ltd
TSE:7747
893.1B JPY
Loading...
US
Lantheus Holdings Inc
NASDAQ:LNTH
5B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
70th
Based on 12 729 companies
70th percentile
60.2%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

Xtant Medical Holdings Inc
Glance View

Market Cap
80.9m USD
Industry
Health Care

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 134 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. The Company’s key spinal implant product lines include Cervical Products, Thoracolumbar Products, Interbody Products, and Interlaminar Stabilization Products.

XTNT Intrinsic Value
0.6355 USD
Undervaluation 9%
Intrinsic Value
Price
X
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
60.2%
=
Gross Profit
$76.9m
/
Revenue
$127.8m
What is Xtant Medical Holdings Inc's current Gross Margin?

The current Gross Margin for Xtant Medical Holdings Inc is 60.2%, which is above its 3-year median of 59.4%.

How has Gross Margin changed over time?

Over the last 3 years, Xtant Medical Holdings Inc’s Gross Margin has increased from 55.1% to 60.2%. During this period, it reached a low of 55.1% on Jun 30, 2022 and a high of 61.6% on Jun 30, 2024.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett